Chester County News and Community Website
WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader, NKT3964, by completing the dosing of the first patient cohort in a …
NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial Read More
SPRING HOUSE, PA — Third Arc Bio Inc. has administered the first dose of ARC101 to a patient in its inaugural first-in-human clinical trial. This milestone marks the company’s transition to …
Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study Read More
PHILADELPHIA, PA— Researchers at The Wistar Institute, led by Jessie Villanueva, Ph.D., have made significant strides in combating treatment-resistant melanoma. Their latest discovery focuses on inhibiting the gene S6K2, a breakthrough …
Wistar Institute Uncovers New Strategy for Treating Resistant Melanoma Read More
SAN DIEGO, CA and PHILADELPHIA, PA — BioAtla, Inc. and Context Therapeutics Inc. have entered into a significant agreement, granting Context an exclusive, worldwide license to develop and commercialize BioAtla’s BA3362, …
BioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment Development Read More
WILMINGTON, DE — Prelude Therapeutics Incorporated this week unveiled interim results from its Phase 1 trial of PRT3789, a pioneering therapy designed to target cancers with a SMARCA4 mutation. The data, …
Prelude Therapeutics Releases Promising Phase 1 Data on Novel Cancer Treatment Read More
BERWYN, PA — Panavance Therapeutics Inc. has announced the publication of encouraging data on misetionamide in the peer-reviewed journal, Cancer Medicine. The study conducted by Kim et al. at MD …
Panavance Therapeutics Reports Positive Data on Misetionamide in Ovarian Cancer Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced a significant addition to its drug pipeline with the acquisition of CT-95 from Link Immunotherapeutics, Inc. The asset is a mesothelin …
Context Therapeutics Acquires Promising Cancer Treatment Asset Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has announced a collaboration with Merck to evaluate a new cancer treatment. The Phase 2 clinical trial will test Prelude’s investigational drug, …
Prelude Therapeutics Joins Forces with Merck for Cancer Treatment Trial Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) has announced that the national supply of cisplatin, a key cancer medication, now exceeds demand, ending a critical shortage that began …
FDA Announces End to National Shortage of Crucial Cancer Drug Cisplatin Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) recently granted accelerated approval to Epkinly (epcoritamab-bysp), a new treatment option for adults with relapsed or refractory follicular lymphoma (FL). This …
FDA Grants Accelerated Approval to New Treatment for Relapsed Follicular Lymphoma Read More